Ask Warren

Chong Kun Dang Pharmaceutical

185750 · KOSPI · ₩185750 · 종근당

₩62,500▲ ₩600 (0.97%)End-of-day · Oct 29, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y −24.70%
STOP ₩65,300DCA3 ₩64,300DCA2 ₩63,300DCA1 ₩62,300Entry ₩61,300TP1 ₩59,300TP2 ₩57,300TP3 ₩54,400TP4 ₩51,400TP5 ₩45,400
Entry, trailing stop, targets and DCA levels of the current Squeeze! setup (paper-trading levels from a fixed rule, not advice).
Market cap
₩863B
Enterprise value
₩1T
P/E
10.9×
P/B
0.8×
Dividend yield
0.8%
ROE
7.8%
Net margin
4.5%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−36.3% from the high

₩61,000Today: ₩61,400 – ₩62,800₩98,100

Returns

  • 1W−4.1%
  • 1M−3.0%
  • 3M−7.0%
  • 6M−27.1%
  • YTD−24.6%
  • 1Y−24.7%
Volume today
11,350
0.6× the 20-day average
Traded today
₩703M
Listed shares
13,802,780
EPS (12 months)
₩5,758
Earnings yield 9.2%
SellBuy
AI research · Update noteChong Kun Dang: Model Fair Value Estimate Rises to ₩88,607 per Share from ₩36,731The evidence is mixed and the change is mainly about the model, not the company.Read the full report →

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

46Normal
  • BuzzNormalBuzz 46: in the news.
  • SentimentPositiveNews: Profit growth in the quarter is positive, though sales growth was only slight. Community: 0 bullish, 0 bearish posts this week.
  • MomentumFlat-4.4% over the last month; the price is below its 20-day average.
  • News impactSome19 news items and filings in two weeks; 0 rated high impact, 1 medium.

Signals describe activity, not recommendations. Not financial advice.

Futures and options

All stock futures →

Futures (2026-11): 61,900

Basis −0.96% · implied rate −25.1%

Open interest 1,112 contracts

Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.

Chong Kun Dang Pharmaceutical stock overview

Chong Kun Dang Pharmaceutical (종근당, KRX: 185750) is listed on KOSPI, in the Biotech & Pharma sector. Jong-keun Dang (Chong Kun Dang) is one of South Korea's large pharmaceutical companies, founded in 1941 as Gungbon Pharmacy and listed on the Korea Exchange since 1976. Its shares closed at ₩62,500 on Oct 29, 2026, up 0.97% on the day, giving it a market value of ₩863B.

Key facts

Market cap
₩863B
Sector
Biotech & Pharma
Latest price change
+0.97%
As of
Oct 29, 2026
Main business
Jong-keun Dang (Chong Kun Dang) is one of South Korea's large pharmaceutical companies, founded in 1941 as Gungbon Pharmacy and listed on the Korea Exchange since 1976.

Quick answers about Chong Kun Dang Pharmaceutical

What does Chong Kun Dang Pharmaceutical do?
Jong-keun Dang (Chong Kun Dang) is one of South Korea's large pharmaceutical companies, founded in 1941 as Gungbon Pharmacy and listed on the Korea Exchange since 1976. The company develops, manufactures and sells prescription drugs (ETC) and over-the-counter drugs (OTC), with a product lineup spanning areas such as osteoporosis, lipid-lowering, diabetes, hypertension, transplant immunosuppressants and cerebrovascular disease treatments. It invests in new drug, improved-drug and generic development, and its products are sold in the Korean pharmaceutical market.
What is the market cap of Chong Kun Dang Pharmaceutical?
The market capitalisation of Chong Kun Dang Pharmaceutical was ₩863B at the close on Oct 29, 2026.
Who are the largest shareholders of Chong Kun Dang Pharmaceutical?
According to the latest official filings, the largest reported holders are Chong Kun Dang Holdings (40.15%, as of Oct 8, 2026); KopernikGlobalInvestors,LLC (8.38%, as of Jun 26, 2026); National Pension Service (6.34%, as of Jul 1, 2026).
When is the next earnings report from Chong Kun Dang Pharmaceutical?
Korean companies rarely announce results dates in advance. Based on when Chong Kun Dang Pharmaceutical filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Does the National Pension Service own Chong Kun Dang Pharmaceutical?
Yes. The National Pension Service held 6.34% of Chong Kun Dang Pharmaceutical shares as of Jul 1, 2026.

Company profile

Jong-keun Dang (Chong Kun Dang) is one of South Korea's large pharmaceutical companies, founded in 1941 as Gungbon Pharmacy and listed on the Korea Exchange since 1976. The company develops, manufactures and sells prescription drugs (ETC) and over-the-counter drugs (OTC), with a product lineup spanning areas such as osteoporosis, lipid-lowering, diabetes, hypertension, transplant immunosuppressants and cerebrovascular disease treatments. It invests in new drug, improved-drug and generic development, and its products are sold in the Korean pharmaceutical market.

Written by AI from the company's latest annual report.

Korean name
종근당
Sector
Biotech & Pharma
Themes
Biotech (new drugs)Contract drug manufacturing (CDMO)Pharmaceuticals
CEO
김영주
Founded
Nov 2013
Listed
Dec 2013
Listed shares
13,802,780
Fiscal year ends
Month 12
Website
www.ckdpharm.com

Similar companies

Recent news

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: Chong Kun Dang Pharmaceutical / 종근당 / 185750 / KRX:185750

Source: KRX statistical information